Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H. Caldwell, Zachary Goodman, Ilan Wapinski, Murray Resnick, Andrew H. Beck, Dora Ding, Catherine Jia, Jen‐Chieh Chuang, Ryan S. Huss, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Keyur Patel, Brian B. Borg, Reem Ghalib, Heidi Kabler, John Poulos, Ziad Younes, Magdy Elkhashab, Tarek Hassanein, Rajalakshmi Iyer, Peter Ruane, Mitchell L. Shiffman, Simone Strasser, Vincent Wai‐Sun Wong, Naim Alkhouri, ATLAS Investigators – 10 November 2020

Coronavirus Disease 2019 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?

Daniel Reis Waisberg, Edson Abdala, Lucas Souto Nacif, Liliana Ducatti, Luciana Bertocco Haddad, Rodrigo Bronze Martino, Rafael Soares Pinheiro, Rubens Macedo Arantes, Flavio Henrique Galvao, Larissa Nunes Gouveia, Debora Raquel Terrabuio, George Felipe Darce, Vinicius Rocha‐Santos, Wellington Andraus, Luiz Augusto Carneiro‐D’Albuquerque – 9 November 2020

Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

Ethan M. Weinberg, Michael P. Curry, Catherine T. Frenette, Fredric G. Regenstein, Eugene R. Schiff, Zachary D. Goodman, James M. Robinson, Jean L. Chan, Joanne C. Imperial, K. Rajender Reddy – 8 November 2020 – Despite achieving sustained virologic response (SVR) to hepatitis C virus (HCV) therapy, there remains a post liver transplantation population with advanced fibrosis/cirrhosis. Emricasan is an orally active, pan‐caspase inhibitor that suppresses apoptosis and inflammation, potentially decreasing hepatic inflammation and fibrosis.

Impacts of Early Kasai Portoenterostomy on Short‐Term and Long‐Term Outcomes of Biliary Atresia

Ryuji Okubo, Masaki Nio, Hideyuki Sasaki, the Japanese Biliary Atresia Society – 8 November 2020 – There are discrepancies regarding the clinical impact of age at Kasai portoenterostomy (KP) on surgical outcomes. Hence, we re‐assessed the clinical significance of age at KP. We analyzed 224 patients with type III (atresia of bile duct at the porta hepatis) biliary atresia at Tohoku University Hospital. We classified patients into two groups: KP at ≤60 days of age (group TE) and >60 days of age (group TL).

Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine Signaling

Jinhang Gao, Bo Wei, Mengfei Liu, Petra Hirsova, Tejasav S. Sehrawat, Sheng Cao, Xiao Hu, Fei Xue, Usman Yaqoob, Ningling Kang, Huarui Cui, William C.K. Pomerantz, Enis Kostallari, Vijay H. Shah – 7 November 2020

A Population‐Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection

John Scott, Meaghan Fagalde, Atar Baer, Sara Glick, Elizabeth Barash, Hilary Armstrong, Kris V. Kowdley, Matthew R. Golden, Alexander J. Millman, Noele P. Nelson, Lauren Canary, Matthew Messerschmidt, Pallavi Patel, Michael Ninburg, Jeff Duchin – 7 November 2020 – Hepatitis C virus (HCV) infection is common in the United States and leads to significant morbidity, mortality, and economic costs. Simplified screening recommendations and highly effective direct‐acting antivirals for HCV present an opportunity to eliminate HCV.

Hepatology Highlights

Nicholas W. Russo, Robert S. Brown, Gopanandan Parthasarathy, Robert E. Schwartz, Adam Buckholz, Arun B. Jesudian, Enis Kostallari, Cesar Taborda, Joel Wedd, Tejasav S. Sehrawat, Navid Hejazifar, Lauren M. Yang, Daryl T.Y. Lau, Jessica Maiers, Nidhi Jalan‐Sakrikar – 6 November 2020

Subscribe to